Chemical Works of Gedeon Richter Plc.

The pharmaceutical company Gedeon Richter Rus will invest 1.2 bln rubles in the expansion of production in the Moscow Region, as stated in the press-release of the Ministry of Investments and Innovations of the Moscow Region.

“The largest foreign pharmaceutical producer decided to expand and modernize their own production. The amount of investment in the project will be 1.2 billion rubles”, as reported by Denis Butsaev, the Deputy Chairman of the Moscow Region Government and the Minister of Investments and Innovations of the Moscow Region, whose words are quoted in the document.

05 September 2017
RIA Novosti

Richter continues to plan expanding its production capacities in Russia, said Erik Bogsch, Chief Executive Officer of Hungary’s leading pharmaceutical producer. 

Setting up and gradual expansion of Richter’s Russian manufacturing plant carries great importance. About 15% of Richter’s sales in Russia are already covered from locally-manufactured products and this ratio is likely to increase further, he added. 

As regards the outlook, Bogsch said international expansion is vital for the company. Whereas Richter needs to keep its profit on generic drug sales it also has to be present on the market of biosimilar products and continue original research in the development of central nervous system drugs too. 

02 September 2014

Investor profile

Chemical Works of Gedeon Richter Plc.


Company's website:

T: +44 (0) 207 604 8800

Public company (RICHTER)


Contact: Erik Bogsch, CEO

Gedeon Richter is the largest biotechnology and pharmaceutical company in Hungary and middle sized globally, presented in nearly 40 countries.